Adamas Pharmaceuticals (NASDAQ: ADMS) is one of 205 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare Adamas Pharmaceuticals to similar companies based on the strength of its analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.
Risk and Volatility
Adamas Pharmaceuticals has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, Adamas Pharmaceuticals’ competitors have a beta of 1.51, meaning that their average stock price is 51% more volatile than the S&P 500.
Earnings & Valuation
This table compares Adamas Pharmaceuticals and its competitors revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Adamas Pharmaceuticals||$570,000.00||-$60.05 million||-8.23|
|Adamas Pharmaceuticals Competitors||$220.75 million||-$39.68 million||-58.98|
Adamas Pharmaceuticals’ competitors have higher revenue and earnings than Adamas Pharmaceuticals. Adamas Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This table compares Adamas Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Adamas Pharmaceuticals Competitors||-3,896.18%||-121.79%||-44.29%|
Insider and Institutional Ownership
71.8% of Adamas Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.0% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 29.0% of Adamas Pharmaceuticals shares are owned by company insiders. Comparatively, 13.6% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a summary of recent ratings and price targets for Adamas Pharmaceuticals and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Adamas Pharmaceuticals Competitors||495||2383||6442||121||2.66|
Adamas Pharmaceuticals presently has a consensus target price of $42.00, suggesting a potential upside of 51.35%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 18.15%. Given Adamas Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Adamas Pharmaceuticals is more favorable than its competitors.
Adamas Pharmaceuticals beats its competitors on 7 of the 12 factors compared.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).
Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.